Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary Melanoma
Clinical trial NCT04133948 · COMPLETED
Trial details
- NCT number
- NCT04133948
- Sponsor
- The Netherlands Cancer Institute
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-01-07
- Primary completion
- 2022-01-11
- Enrollment
- 44
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.